ArticleAJNR. American journal of neuroradiology2017
What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.
Article in AJNR. American journal of neuroradiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Imaging vascular and hemodynamic features of the brain using dynamic susceptibility contrast and dynamic contrast enhanced MRI.NeuroImage · 2019Pooled it
- First-in-Human Study of the Carbohydrate NanoparticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Designing Water-Soluble Macromolecules for Biomedical Use: PEG Chains versus Amino AcidsA Case Study in MRI Contrast Agents.ACS polymers Au · 2026Article
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.AJR. American journal of roentgenology · 2023Article
- Low-field MRI: Clinical promise and challenges.Journal of magnetic resonance imaging : JMRI · 2023Review
- Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis.Abdominal radiology (New York) · 2021Review
- USPIOs as targeted contrast agents in cardiovascular magnetic resonance imaging.Current cardiovascular imaging reports · 2021Article
- Quantitative Imaging of Blood-Brain Barrier Permeability Following Repetitive Mild Head Impacts.Frontiers in neurology · 2021Article
- Cardiac Magnetic Resonance Quantification of Structure-Function Relationships in Heart Failure.Heart failure clinics · 2021Review
- Contrast enhanced magnetic resonance imaging highlights neurovasculature changes following experimental traumatic brain injury in the rat.Scientific reports · 2020Article
- Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.AJR. American journal of roentgenology · 2020Article
- Potential Toxicity of Iron Oxide Magnetic Nanoparticles: A Review.Molecules (Basel, Switzerland) · 2020Review
- Article
- Measurements of cerebral blood volume using quantitative susceptibility mapping, RNMR in biomedicine · 2019Article
- Topics on quantitative liver magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2019Review
- Measurement of microvascular cerebral blood volume changes over the cardiac cycle with ferumoxytol-enhanced TMagnetic resonance in medicine · 2019Article
- High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2019Article
- Ferumoxytol-enhanced MRI in the peripheral vasculature.Clinical radiology · 2019Review
- Blood volume measurement using cardiovascular magnetic resonance and ferumoxytol: preclinical validation.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
background and purposeDespite the label change and the FDA's boxed warning added to the Feraheme (ferumoxytol) label in March 2015, radiologists have shown increasing interest in using ferumoxytol as an MR imaging contrast agent as a supplement or alternative to gadolinium. The goals of this study were to provide information regarding ferumoxytol safety as an imaging agent in a single center and to assess how the Feraheme label change may affect this potential, currently off-label indication. MATERIALS AND
methodsThis retrospective study evaluated the overall frequency of ferumoxytol-related adverse events when used for CNS MR imaging. Patients with various CNS pathologies were enrolled in institutional review board-approved imaging studies. Ferumoxytol was administered as multiple rapid bolus injections. The risk of adverse events was correlated with demographic data/medical history.
resultsThe safety of 671 ferumoxytol-enhanced MR studies in 331 patients was analyzed. No anaphylactic, life-threatening, or fatal (grade 4 or 5) adverse events were recorded. The overall proportion of ferumoxytol-related grade 1-3 adverse events was 10.6% (8.6% occurring within 48 hours), including hypertension (2.38%), nausea (1.64%), diarrhea (1.04%), and headache (1.04%). History of 1 or 2 allergies was associated with an increased risk of adverse events (14.61% versus 7.51% [no history];
conclusionsThe frequency of mild ferumoxytol-related adverse events was comparable with literature results, and no serious adverse event was recorded. Although the recommendations in the boxed warning should be followed, serious adverse events appear to be rare, and with proper precautions, ferumoxytol may be a valuable MR imaging agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.